|
 |
|
|||||||
|
|||||||||
Diabetes 51:3486-3491, 2002
© 2002 by the American Diabetes Association, Inc.
Mechanisms of the Triglyceride- and Cholesterol-Lowering Effect of Fenofibrate in Hyperlipidemic Type 2 Diabetic Patients
1 INSERM U 499, Faculté RTH Laennec, Lyon, France
2 Research Center for Human Nutrition, Hôpital Ed. Herriot, Lyon, France
In humans, the precise mechanisms of the hypolipidemic action of fenofibrate, a peroxisome proliferator-activated receptor-
agonist, remain unclear. To gain insight on these mechanisms, we measured plasma lipids levels, lipids synthesis (hepatic de novo lipogenesis and cholesterol synthesis), and mRNA concentrations in circulating mononuclear cells (RT-PCR) of hydroxymethylglutaryl (HMG)-CoA reductase, LDL receptor, LDL receptor- related protein (LRP), scavenger receptor class B type I (SR-BI), ABCAI, and liver X receptor (LXR)- in 10 control subjects and 9 hyperlipidemic type 2 diabetic patients. Type 2 diabetic subjects were studied before and after 4 months of fenofibrate administration. Fenofibrate decreased plasma triglycerides (P < 0.01) and total cholesterol (P < 0.05) concentrations and slightly increased HDL cholesterol (P < 0.05). Hepatic lipogenesis, largely enhanced in diabetic subjects (16.1 ± 2.1 vs. 7.5 ± 1.6% in control subjects, P < 0.01), was decreased by fenofibrate (9.8 ± 1.5%, P < 0.01). Fractional cholesterol synthesis was normal in diabetic subjects (3.5 ± 0.4 vs. 3.3 ± 0.5% in control subjects) and was unchanged by fenofibrate (3.5 ± 0.5%). Absolute cholesterol synthesis was, however, increased in diabetic subjects before and after fenofibrate (P < 0.05 vs. control subjects). HMG-CoA reductase, LDL receptor, LRP, and SR-BI mRNA concentrations were not different in type 2 diabetic and control subjects and were unchanged by fenofibrate. LXR- mRNA levels were increased (P < 0.05) by fenofibrate. ABCAI mRNA concentrations, which were decreased in diabetic subjects (P < 0.05) before fenofibrate, were increased (P < 0.05) by fenofibrate to values comparable to those of control subjects. The plasma triglyceride-lowering effect of fenofibrate is explained in part by a decrease in hepatic lipogenesis, the moderate fall in total plasma cholesterol is not explained by a reduction of whole-body cholesterol synthesis, and the increase in LXR- and ABCAI mRNA levels suggests that fenofibrate stimulated reverse cholesterol transport.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. M. Schroeder-Gloeckler, S. M. Rahman, R. C. Janssen, L. Qiao, J. Shao, M. Roper, S. J. Fischer, E. Lowe, D. J. Orlicky, J. L. McManaman, et al. CCAAT/Enhancer-binding Protein beta Deletion Reduces Adiposity, Hepatic Steatosis, and Diabetes in Leprdb/db Mice J. Biol. Chem., May 25, 2007; 282(21): 15717 - 15729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bilz, V. Samuel, K. Morino, D. Savage, C. S. Choi, and G. I. Shulman Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters Am J Physiol Endocrinol Metab, April 1, 2006; 290(4): E716 - E722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Forcheron, L. Legedz, G. Chinetti, P. Feugier, D. Letexier, G. Bricca, and M. Beylot Genes of Cholesterol Metabolism in Human Atheroma: Overexpression of Perilipin and Genes Promoting Cholesterol Storage and Repression of ABCA1 Expression Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1711 - 1717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Letexier, C. Pinteur, V. Large, V. Frering, and M. Beylot Comparison of the expression and activity of the lipogenic pathway in human and rat adipose tissue J. Lipid Res., November 1, 2003; 44(11): 2127 - 2134. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |